Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
Key Highlights
- ➤Responders’ Skindex-29 scores improved 5.38–13.69 points across assessments
- ➤Responders’ FACT-G scores improved 3.21 points at treatment end versus non-responders
- ➤13 of 41 heavily pretreated patients achieved sustained clinically meaningful itch improvement
- ➤LYMPHIR launched in U.S. December 2025 after FDA approval for Stage I–III CTCL
Expert Statements
Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology
“Patients and physicians have told us that both clinical response and quality of life matter in CTCL treatment”
Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology
“These data add the patient's voice to the efficacy and durability shown in our pivotal trial.”
Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology
“We were pleased to share the data at the EORTC-CLTG conference in Berlin and are proud to partner with the Cutaneous Lymphoma Foundation on its November 2026 workshop to put quality of life at the center of CTCL care.”
Myron Czuczman, Chief Medical Officer of Citius Oncology
“CTCL is a disease of the skin which symptomatic patients must deal with 24/7.”
Myron Czuczman, Chief Medical Officer of Citius Oncology
“Painful, itchy lesions take a real toll on their well-being”
Myron Czuczman, Chief Medical Officer of Citius Oncology
“In Study 302, patients who responded to denileukin diftitox-cxdl reported sustained quality of life improvements, and nearly a third of heavily pretreated patients with significant itch noted its decrease.”
Myron Czuczman, Chief Medical Officer of Citius Oncology
“We believe these findings underscore how important quality of life considerations are as practitioners choose between various treatment options for their patients with relapsed or refractory CTCL.”
Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe PR Newswire
Data featured in oral presentation at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting in Berlin
Get started
Create a free account to read the full story.